Biotech lead generation that fills your pipeline with qualified research and procurement buyers.

Outreach starts in week one. Target-list build, messaging, and account research finish during onboarding, so day one of the engagement is dialing day — we don’t ramp by quarter. First qualified appointments typically land within the first week, with steady weekly cadence by week three. Your team sees meetings on the calendar before most agencies have finished writing their kickoff deck.

Three-point standard, and all three must be met. Verified pain — the buyer has named a specific assay, workflow, capacity, or compliance problem, not just mild curiosity. Decision authority — they can sign for it, or they’re one of two people who can. Active timeline — they’re evaluating in the next 90 days, not “maybe next grant cycle.” Anything short of all three doesn’t make your calendar. Most agencies count anything with a pulse as a “lead.” We don’t.

Yes — our life-sciences mix splits across both. Selling a benchtop instrument or reagent line is a different motion from selling a multi-year CRO or CDMO engagement: different buyers, different cycle length, different objection patterns. We tune the messaging and qualification standard to what you actually sell — not a generic “life sciences” pitch.

We sequence engagement by stakeholder. The bench scientist or PI enters first — they spec the fit and sponsor it internally. Procurement, lab ops, and QA/regulatory enter later, at the terms and compliance stage. Our SDRs stay involved through the nurture phase so the handoff to your AE doesn’t reset the conversation. A 12-month, grant-tied decision can’t survive being thrown over a wall at month four — our model is built so it doesn’t have to.

Mid-market through enterprise — most clients land between $20M and $2B in revenue. The common thread isn’t size, it’s commercial infrastructure: you need an AE, field application scientist, or account team able to run a demo and close once qualified meetings hit the calendar. If you’re earlier-stage without that motion in place, we’ll tell you upfront.

Onboarding runs five to ten business days from kickoff. We use that window to build the target list, finalize your messaging, train SDRs on your modality, workflows, and service tiers, and integrate with your CRM. Most kickoff work compresses into two or three short working sessions — your time stays minimal. Messaging gets iterated weekly through the first month based on real call data — what’s landing, what isn’t, where to adjust. The point is to sound like your team, not another agency reading from a deck.

Yes, and segmentation goes deeper than a SIC pull. We layer modality (small molecule, biologics, cell and gene therapy, diagnostics), research stage (discovery, preclinical, clinical, commercial), funding source, instrument install base, certification status (GMP, GLP, CLIA, ISO), revenue band, and institution type. The output is a tight list of accounts that actually fit your offer. Sloppy targeting is the single biggest reason biotech lead generation campaigns underperform. We fix it before week one.

Monthly retainer, scoped to your target volume, account complexity, and sales-cycle length. Enterprise pharma targets and long CRO/CDMO cycles cost more to engage; smaller mid-market plays cost less. We don’t publish a rate card because each life-sciences offer looks different, and a flat price would either overcharge half our clients or undercharge the other half. Book the assessment and you’ll get a written scope and quote within 30 minutes of the call.